Article
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Melanoma research - 1 Jun 2022
Awada Gil, Schwarze Julia Katharina, Tijtgat Jens, Fasolino Giuseppe, Kruse Vibeke, Neyns Bart
Abstract excerpt
Patients with advanced BRAFV600 mutant melanoma who progressed on prior treatment with BRAF-/MEK-inhibitors and programmed cell death 1 or cytotoxic T-lymphocyte-associated antigen 4 immune checkpoint inhibitors can benefit from retreatment with the combination of a BRAF- and a MEK-inhibitor ('rechallenge'). Hydroxychloroquine can prevent autophagy-driven resistance and improve the efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.